What Eli Lilly Stock Said When It Had Too Much Business

Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.

It’s one of the market’s great ironies: the best sign a stock is about to run isn’t always a story about finding growth. Sometimes, it’s a story about having to tame it.

Before Eli Lilly (LLY) surged nearly 56% in the year to mid-2026, the company wasn’t just growing; it was actively throttling its own demand. The evidence was assembling itself not in a secret memo, but right there in the public record, for anyone piecing together the clues.

How fast was the business already accelerating?

First, the engine was already redlining. As of its fiscal Q1 2025 report, the last one before the run, Lilly’s revenue over the trailing twelve months was up 36.4%. That wasn’t just good; it was a sharp acceleration from its three-year average growth of 20.2%. The company’s operating margin for that quarter hit 40.2%, a world away from its 30.9% three-year average. The business wasn’t just getting bigger; it was getting more profitable at a faster clip.

What was management pointing to next?

This is where it gets interesting. While investors were rightly focused on the blockbuster sales of injectable drugs like Mounjaro and Zepbound, management was already talking about the next act. On the May 2025 earnings call, when an analyst asked about a competitor gaining preferential treatment from a pharmacy benefit manager, the CEO’s response was telling. He didn’t just defend his current products. He pivoted.

“Our focus is on making better medicines and more accessible medicines,” he said, before immediately adding: “So our orforglipron is a topic today, excited by the possibility of an oral that could be more widely distributed.”

He was answering a question about a competitive skirmish by pointing to a strategic game-changer: an oral GLP-1 pill. The company’s stated goal was to create a medicine with “injectable GLP-1 like efficacy” that could be “manufactured at scale to meet global demand.” They were signaling that while everyone was watching the current battle, they were already building the next-generation portfolio differentiator.

Why was the company holding back on advertising?

The clearest tell, however, came from what the company wasn’t doing. In late 2024, the finance chief explained that Lilly had been “prudent scaling up and our demand-generation activities.” In plain English: they were deliberately keeping a lid on marketing. Why? Because they were struggling to make enough product to satisfy the customers they already had.

The company then signaled it would “accelerate demand activities” into 2025 as supply caught up. It was a direct forecast of a growth inflection. The options market seemed to sense something was brewing, too. Just before the surge, implied volatility sat in the 85th percentile of its annual range, meaning traders were braced for a big move, though the direction was anyone’s guess.

This was the sound of a company whose biggest challenge wasn’t finding the next mountain to climb, but building a base camp big enough to support the expedition.

How Do You Get Ahead Of The Next One?

Not by listening harder; no individual can monitor thousands of companies that closely. The practical edge is to watch the one signal that is public and trackable: a guidance raise. Our Guidance Momentum rankings show which S&P 500 names are flashing it now, with momentum to match. But guidance is one signal among many. The Trefis High Quality (HQ) Portfolio weighs the full picture of quality across thousands of names, holds the 30 strongest, re-balances them with rules, and has outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.